Lv21
120 积分 2020-10-04 加入
Management of Perianal Crohn's Disease
4小时前
已完结
Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders
1年前
已关闭
Risk of Tuberculosis and Hepatitis B Reactivation in Patients With Crohn's Disease on Ustekinumab: A Nationwide Real-World Study
2年前
已完结
Long-Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases
2年前
已完结
Immunomodulatory Effect of Serum Exosomes From Crohn Disease on Macrophages via Let-7b-5p/TLR4 Signaling
2年前
已完结
Enterotoxigenic Bacteroides fragilis Promotes Intestinal Inflammation and Malignancy by Inhibiting Exosome-Packaged miR-149-3p
2年前
已完结
Biopsy and blood-based molecular biomarker of inflammation in IBD
2年前
已完结
Depression and Inflammatory Bowel Disease: A Bidirectional Two-sample Mendelian Randomization Study
2年前
已完结
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial
2年前
已完结
Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn’s disease
2年前
已完结
皖公网安备34019202002308
